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Abstract
Background: Proteases of human pathogens are becoming increasingly important drug targets,
hence it is necessary to understand their substrate specificity and to interpret this knowledge in
practically useful ways. New methods are being developed that produce large amounts of cleavage
information for individual proteases and some have been applied to extract cleavage rules from
data. However, the hitherto proposed methods for extracting rules have been neither easy to
understand nor very accurate. To be practically useful, cleavage rules should be accurate, compact,
and expressed in an easily understandable way.
Results:  A new method is presented for producing cleavage rules for viral proteases with
seemingly complex cleavage profiles. The method is based on orthogonal search-based rule
extraction (OSRE) combined with spectral clustering. It is demonstrated on substrate data sets for
human immunodeficiency virus type 1 (HIV-1) protease and hepatitis C (HCV) NS3/4A protease,
showing excellent prediction performance for both HIV-1 cleavage and HCV NS3/4A cleavage,
agreeing with observed HCV genotype differences. New cleavage rules (consensus sequences) are
suggested for HIV-1 and HCV NS3/4A cleavages. The practical usability of the method is also
demonstrated by using it to predict the location of an internal cleavage site in the HCV NS3
protease and to correct the location of a previously reported internal cleavage site in the HCV NS3
protease. The method is fast to converge and yields accurate rules, on par with previous results
for HIV-1 protease and better than previous state-of-the-art for HCV NS3/4A protease. Moreover,
the rules are fewer and simpler than previously obtained with rule extraction methods.
Conclusion: A rule extraction methodology by searching for multivariate low-order predicates
yields results that significantly outperform existing rule bases on out-of-sample data, but are more
transparent to expert users. The approach yields rules that are easy to use and useful for
interpreting experimental data.
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Background
The human body contains almost 600 proteases [1] that
are involved in a number of important biological path-
ways such as blood coagulation, fibrinolysis, complement
activation, hormone production and digestion [2]. These
proteases are often essential players in elaborate networks,
or cascades, where zymogens (catalytically inactive pro-
tease precursors) are activated in order to activate a down-
stream zymogen or digest/inactivate a structural or
biologically active protein. Proteases therefore tend to
have highly specific substrate repertoires and are regulated
by endogenous protease inhibitors, with a delicate bal-
ance between these counteracting forces. An imbalance
between active proteases and protease inhibitors may
cause, or contribute to, many diseases. A classical example
is hereditary deficiency of α1 proteinase inhibitor (also
known as antitrypsin), that can lead to early-onset emphy-
sema [3]. This process is greatly accelerated upon smok-
ing, partly because antitrypsin is susceptible to
inactivation by oxidation by cigarette smoke and because
neutrophil elastase, a potent protease with a broad sub-
strate specificity including lung elastin, is up-regulated
and released from neutrophils by nicotine. Similarly, the
progression of some severe diseases can be successfully
slowed down with the use of protease inhibitors. Pro-
teases are consequently important drug targets [4] and the
list of protease inhibitors approved for clinical use is
steadily growing, including drugs to treat, e.g., hyperten-
sion, thrombosis, pancreatitis, periodontitis, respiratory
diseases, cancer, HIV/AIDS and probably soon hepatitis C
[5]. However, the road to success has been paved with
numerous failures, because of many unexpected (and in
most cases unwanted) side effects. An ideal protease
inhibitor should have a well defined substrate specificity,
broad enough to treat the disease efficiently, but narrow
enough not to interfere with other proteases or biological
processes, combined with low toxicity to the host cells.
HIV-1 protease has an important function for virus matu-
ration during HIV infection, but its substrate specificity is
complex and endogenous protease inhibitors of the host
cells infected with HIV do not seem to be able to stop its
action. Therefore, artificial HIV-1 protease inhibitors are
needed and have been in clinical use for HIV/AIDS treat-
ment for over a decade. Among other viral targets, the
hepatitis C virus (HCV) NS3 protease is also a candidate
target for antiviral drugs, since currently available HCV
therapy is effective in only half of the patients and limited
by serious side effects [6,7].
A challenge in the hunt for better protease inhibitors is to
make maximum use of available experimental protease
data and provide accurate rules for the substrate specifi-
city, rules that can be used to estimate the effect of pro-
teases in biological pathways. There are three important
criteria that should be met by these specificity rules: they
should be accurate in terms of out-of-sample prediction;
they should be comprehensible (understandable); and
they should have a high fidelity to the data from which
they were extracted. The aim of the present work was to
present a method for extracting cleavage rules from viral
protease data. A method that provides rules that meet
these three criteria better than previously presented
approaches. The method is exemplified on HIV-1 and
HCV NS3 protease data sets.
The structure of cleavage rules
The first step towards meeting the three requirements
above (accuracy, comprehensibility, and fidelity) is to
understand how cleavage rules are typically formulated.
Rules that are expressed in the standard form are probably
more likely to be comprehensible, and they may even be
more accurate if the standard form has developed over
time so that people have included their knowledge of how
protease cleavage works into these rules.
Cleavage specificities tend to be described assuming that
certain positions should contain certain amino acids.
Common terms used are "consensus motif" (or "consen-
sus sequence") and "sub-site preference" (see e.g. [8]),
where the latter refers to those amino acids that seem to
match the active site in the protease, and sub-site prefer-
ences are typically illustrated with specificity profiles or
histograms showing the frequency of amino acids in the
different positions of cleaved substrates. This assumption
is evident in the rules used for different proteases in the
tools PeptideCutter and PeptideMass on http://
www.expasy.ch; they are all expressed as lists of allowed
(or disallowed) amino acids in the positions of the pep-
tides (examples are provided below).
The tradition of expressing cleavage rules in this fashion
may not be a coincidence, and a rule extraction method
that explicitly produces conjunctive rules may therefore
be the right way to go for these problems.
Conjunctive rules are rules that are formulated as lists of
requirements that must all be true (i.e. the requirements
for each position are connected with a logical AND).
Using conjunctive rules puts no restriction on the possible
cleavage specificities that can be described; conjunctive
rules can be combined with the logical OR function into
any logical rule. This is the so-called Disjunctive Normal
Form Theorem [9].
A very simple cleavage rule is, e.g., the Arg-C proteinase
cleavage rule [10]. It cleaves peptides on the C-terminal
side of Arginine (Arg, R). This is expressed as
Arg-C P R 1∈{}BMC Bioinformatics 2009, 10:149 http://www.biomedcentral.com/1471-2105/10/149
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using the standard Schechter and Berger notation [11]
where the substrate sites are denoted by ...-P3-P2-P1-P1'-
P2'-P3'-..., with the scissile bond located between P1 and
P1'.
An effective immune response of the human host against
a viral attack involves the generation of virus-specific cyto-
toxic T lymphocytes (CTLs), whose main function is to kill
virus-infected cells. The two important countermeasures
used by the CTLs are perforin/granzyme mediated apop-
tosis and Fas-mediated apoptosis. Granzyme B, a member
of the hematopoietic serine protease superfamily, is
stored in granules of cytotoxic T cells and natural killer
cells and has a requirement for Aspartate (Asp, D) in the
P1 position [12]. However, the full rule is a conjunctive
rule that involves more positions [13]:
which means that it cleaves on the C-terminal side of the
sequence IEPD, Isoleucine-Glutamate-Proline-Aspartate
(Ile-Glu-Pro-Asp), i.e. all four positions must have specific
amino acids in them for cleavage to occur.
Each position can also allow a set of amino acids, as is the
case for the bovine coagulation factor, Factor Xa [14]:
This means that position P4 should be occupied by any of
{A,G,I,L,T,V,M}, but nothing else, that position P3
should be occupied by any of {D,E}, but nothing else,
that P2 should be occupied by G, and that P1 should be
occupied by R for cleavage to occur (and it occurs on the
C-terminal side of R).
There are also proteases that have more than one rule, e.g.
if there are two types of cleavages that occur. This is the
case for Thrombin [10], which has the following two
cleavage rules:
and
The notation for positions P1' and P2' means that cleav-
age will not occur if Aspartate (Asp, D) or Glutamate (Glu,
E) are in any of those positions.
Combinations of conjunctive rules can also be used to
describe cleavage rules if there are interactions and com-
petitions among the positions. Assume for instance a
cleavage site with two nearby positions (P2 and P1) with
preference for hydrophobic amino acids, e.g. L, M, F, Y
(Leucine, Methionine, Phenylalanine and Tyrosine).
Assume also that it is impossible to fit both positions with
F or Y at the same time (due to space constraints) but that
it is sufficient that one of them is present in one of the two
positions. This would lead to a set of two conjunctive rules
and
To conclude, conjunctive rules follow the notation used in
standard tools for describing cleavage of peptides and
they can be used to describe any type of rule. If conjunc-
tive rules can be used to produce cleavage rules that are
simpler but as accurate as those from other methods that
do not follow the standard notation, then that would
speak in favour of a conjunctive rule approach.
Results
Data
HIV-1 protease data
You et al. [15] collected a HIV-1 protease substrate data set
containing 746 octamers, of which 401 are cleaved and
345 are non-cleaved. In this data set, the octamer SQN-
YAIVQ was originally erroneously labeled as non-cleaved
[16]. This error was corrected and the resulting data set is
referred to as the HIV-1 PR 746 data set in this study. The
octamers are denoted P4-P3-P2-P1-P1'-P2'-P3'-P4'.
Kontijevskis et al. [17] collected a substantially larger HIV-
1 protease substrate data set containing 1625 octamers,
where 374 are cleaved and 1251 are non-cleaved. This
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data set also has the wrong label for SQNYAIVQ, which
we corrected. The corrected data set is referred to as the
HIV-1 PR 1625 data set in this study.
The similarity between the HIV-1 PR 746 and the HIV-1
PR 1625 data sets is very high since they were partly col-
lected from the same literature sources. There are 659
octamers that are common between the HIV-1 PR 746 and
the HIV-1 PR 1625 data sets. Of these, seven are labeled
differently in the two data sets: AAAMSSAI, ARVLAQAM,
GRINVALV, SGVFSVNG and SGVYQLSA are labeled as
cleaved in the 746 data set and as non-cleaved in the 1625
data set; AEAMSQVT and FRSGVETT are labeled as non-
cleaved in the 746 data set and as cleaved in the 1625 data
set.
Recently, Schilling and Overall [8] collected an even larger
set of peptides cleaved by HIV-1 protease. This set was
published after the rules described herein were con-
structed and can thus be used as independent test data. A
set of octamers was generated from this data in the follow-
ing way: cleaved octamers were taken from all peptides
that contained at least four residues on the prime and the
non-prime sides of the scissile bond; non-cleaved octam-
ers were generated by sliding a window of size eight resi-
dues on both sides of the scissile bond (but not across the
scissile bond) if the prime or the non-prime side had at
least eight residues. For example, Schilling and Overall [8]
(supplementary Table nineteen) report the cleaved pep-
tide PLLGGSLMEYAILSAIAAMNEPK, where the cleavage
site is between Y and A. This produces the cleaved octamer
LMEYAILS and the non-cleaved octamers PLLGGSLM,
LLGGSLME, LGGSLMEY, AILSAIAA, ILSAIAAM,
LSAIAAMN, SAIAAMNE, AIAAMNEP and IAAMNEPK.
Peptides that had an ambiguous P1 residue or that were
marked "excluded" in Tables nineteen and twenty in the
supporting material to their paper [8] were removed.
The final data set contains 3261 octamers, of which 436
are cleaved and 2825 are non-cleaved. We refer to this as
the HIV-1 PR 3261 data set.
There is no overlap between the HIV-1 PR 746 and the
HIV-1 PR 3261 data sets. There are twenty common
octamers in the HIV-1 PR 1625 and the HIV-1 PR 3261
data sets, of which two are in conflict (EENFAVEA and
QEEMLQRE, which are both labeled as non-cleaved in the
1625 data set but as cleaved in the 3261 data set). There is
only one sequence in the HIV-1 PR 3261 data set that dif-
fers by one position from any octamer from any sequence
in the HIV-1 PR 746 or HIV-1 PR 1625 data sets. This
sequence is GWVLGEHG, which is labeled as cleaved and
differs in one position from the cleaved GWILGEHG in
the HIV-1 PR 746 and HIV-1 PR 1625 data sets. There are
two sequences in the HIV-1 PR 746 data set that differ in
two positions from sequences in the HIV-1 PR 3261 data
set: the cleaved ARVLFDAL, which is similar to the non-
cleaved APVLLDAL in the HIV-1 PR 3261 data set, and the
cleaved GWILAEHG, which is similar to the cleaved GWV-
LGEHG in the HIV-1 PR 3261 data set. There are four
sequences in the HIV-1 PR 1625 data set that differ in two
positions from sequences in the HIV-1 PR 3261 data set:
the non-cleaved NKILLAEL, VDKLVSAG and TEEKIKAL,
which are similar to the non-cleaved octamers NKVN-
LAEL, VDVLVSSG and TEDKINAL, and the cleaved
octamer GWILAEHG that differs in two positions from the
cleaved GWVLGEHG in the HIV-1 PR 3261 data set. All
other sequences in the HIV-1 PR 3261 data set differ in at
least three positions out of eight from any octamer in the
HIV-1 PR 746 or the HIV-1 PR 1625 data sets.
It is also relevant to check how many sequences in the
data sets that have identical residues in the most impor-
tant positions in the octamer: P2-P1-P1'-P2'. About 92%
of the octamers in the HIV-1 PR 746 data set are identical,
in the four central positions, to sequences in the HIV-1 PR
1625 data set. However, only 7% of the octamers in the
HIV-1 PR 746 data set match to sequences in the HIV-1
3261 data set. About 41% of the octamers in the HIV-1 PR
1625 data set are identical to sequences in the HIV-1 PR
746 data set, but only 7% of the octamers in the HIV-1 PR
1625 data set match sequences in the HIV-1 PR 3261 data
set. About 1% of the sequences in the HIV-1 PR 3261 data
set match to sequences in the HIV-1 PR 746 data set, and
4% match to sequences in the HIV-1 PR 1625 data set.
There is thus very little sequence similarity between the
HIV-1 PR 3261 data set and the HIV-1 PR 746 or the HIV-
1 PR 1625 data sets, while there is a lot of sequence simi-
larity between the two smaller data sets. The smaller data
sets are used to extract cleavage rules, which are then
tested on the larger (3261) data set.
HCV protease data
We initially intended to use a HCV NS3 protease data set
used previously by other researchers [18-22]. There were,
however, several uncertainties and conflicts between this
data set and available references on HCV NS3 cleavage
[23-30], which made us doubt the quality of this data set.
A new HCV NS3 data set was therefore created from
scratch from the references. A procedure described by [18]
was followed to generate 706 additional non-cleaved
decamers by moving a ten residue window over the 4B, 5A
and 5B non-structural proteins [31] of the HCV polypro-
tein [GenBank: AJ238799], excluding the cleavage sites
themselves since they were already in the data set. The 4A
part was excluded since it is a protease co-factor. The
decamers are of the form P6-P5-P4-P3-P2-P1-P1'-P2'-P3'-
P4', i.e. the cleavage occurs between position six and seven
in the decamer. The final HCV NS3 data set contains 939BMC Bioinformatics 2009, 10:149 http://www.biomedcentral.com/1471-2105/10/149
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decamers, of which 199 are cleaved and 740 are non-
cleaved. We denote this data set the HCV NS3 data set.
The HCV NS3 data set is quite different from the data set
used in previous rule extraction studies [18-22]: 8% of the
decamers that occur in both sets are labeled differently.
Three separate out-of-sample test data sets for HCV were
created. The NS3 protease itself [GenBank: NP_803144]
was used to generate one test data set with 621 decamers,
of which none are in the HCV NS3 data set. This test data
set was intended for comparison with reported internal
cleavage sites in the NS3 protease [32-34]. Four proteins
from the TLR3 pathway were used for another test data set:
IκB kinase ε (IKKε) [GenBank: AAC51216]; TRAF family
member-associated NF-κB activator-binding kinase 1
(TBK1) [GenBank: NP_037386]; Toll-like receptor 3
(TLR3) [GenBank: NP_003256]; and Toll-IL-1 receptor
domain-containing adaptor inducing IFN-β  (TRIF or
TICAM-1) [GenBank: BAC55579]. These four proteins
have been tested for HCV NS3 cleavage by Li et al. [35].
The four proteins produced a total of 2805 decamers, of
which one is also in the HCV NS3 data set (the only
observed cleavage site in TRIF). A third test data set was
made up of 69 in vivo tested NS3 substrates from Kim et
al. [36], none of which are in the HCV NS3 data set. The
three out-of-sample test sets are denoted NS3 internal,
TLR3, and NS3 in vivo, respectively.
Artificial data
Two artificial data sets were created to measure the orthog-
onal search-based rule extraction (OSRE) method's ability
to extract rules of the form that we are looking for. The
data sets were designed using conjunctive rules to mimic
typical cleavage rules as described in the introduction.
The two artificial rule sets are shown in Table 1. The sim-
pler problem (A) was modeled partly after the Thermo-
lysin [10] specificity, as described for the PeptideCutter
tool. Four positions were used instead of the minimum
two in order to see how well OSRE could deal with irrele-
vant information. The more complex problem (B) was
modeled after the Thrombin [10] specificity, as described
for the PeptideCutter tool. Training peptides from data set
A were sampled randomly. Training peptides from data
set B were picked with balanced sampling (i.e. achieving a
1:1 ratio of cleaved to non-cleaved sequences). This was
done because the random probability for observing a
cleaved peptide for data set B is very low.
The power of OSRE – the artificial data
Table 2 lists the OSRE rules extracted for the two artificial
protease specificity problems for different sizes of the
training data sets. Problem A is easy but problem B is quite
a lot trickier. OSRE quickly finds the rule (P2 ∈ {P} AND
P1 ∈ {R}) and this simple rule is sufficient to get very high
classification accuracy (approximately 99.7% correct) on
the data. A huge amount of additional data is then
required before the full rule is extracted. This is because a
very low fraction of the negative examples are in conflict
with this rule. OSRE extracts the almost correct rule when
it is presented with a data set with 100,000 examples.
HIV-1 protease
Rule extraction
Rules for the HIV-1 PR 746 and HIV-1 PR 1621 data sets
were extracted using OSRE, as described in the Methods
section. OSRE produced slightly different numbers of
rules for each cross validation (CV) subset, varying
between 7 and 10 rules for the 746 peptide data set and
between 6 and 9 rules for the 1625 peptide data set. The
CV generalization error was estimated for the rules when
one, two, three, four, five and all rules were used to predict
cleavage for the hold-out CV data set (rules were ordered
in priority order by OSRE); this CV error is shown in Fig-
ure 1 and Figure 2. The 746 peptide set is a bit more diffi-
cult to predict because it is a balanced data set with fewer
negative examples than the 1625 peptide set. The CV per-
formance improves until five rules are used (this was one
motivation for using five clusters in the rule clustering).
The CV prediction accuracies of the OSRE method when
using all rules are 87% for the 746 peptide data set and
93% for the 1625 peptide set.
Table 1: Artificial data set.
Artificial data set A (4-mers: P2-P1-P1'-P2') Artificial data set B (6-mers: P4-P3-P2-P1-P1'-P2')
P1' ∈ {A,I,L,M,F,V} P4 ∈ {A,G,I,L,M,F,T,V}
P2' ∉ {P} P3 ∈ {A,G,I,L,F,T,V,W}
P2 ∈ {P}
P1 ∈ {R}
P1' ∉ {D,E}
P2' ∉ {D,E}
Rules for the two artificial data sets used. occur.
Any amino acid could occupy the two first positions in artificial data set A (the generated peptides were longer than the actual rule). One letter 
amino acid abbreviations are used. The sign ∈ means "in" and the sign ∉ means "not in". The rules are connected with the Boolean AND operator, 
which means that all position rules must be true for cleavage to BMC Bioinformatics 2009, 10:149 http://www.biomedcentral.com/1471-2105/10/149
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The fidelity is measured by using the rules to label the
peptide data sets from which they were generated. The
OSRE consensus rules, produced by using spectral cluster-
ing on the OSRE rule sets (as described in the Methods
section), are listed in Table 3. These consensus rules were
used to label the HIV-1 PR peptides in the data sets and
the resulting in-sample accuracy (we denote this the fidel-
ity) is shown in Table 4. Table 4 also lists, for reference,
the fidelities for rule sets generated using the rough set
theory approach [17].
Out-of-sample tests
The OSRE rules' prediction accuracy was tested on the
HIV-1 PR 3261 data set. This data set was published after
the rules were extracted and there is almost no sequence
overlap with the data set used to generate the rules. It
therefore constitutes a true out-of-sample test of the rules'
ability to predict cleavage for novel sequences. However,
the HIV-1 PR 3261 data set has many more non-cleaved
octamers than cleaved octamers; the prediction accuracy is
almost 87% if all sequences are predicted as non-cleaved
(which is not a very useful prediction). The prediction
accuracy is therefore not a good quality measure for the
performance of the rules, it is better to present the sensi-
Table 2: OSRE performance on artificial data set. 
Artificial data set A Artificial data set B
Data OSRE rule Data OSRE rule
10 P2 ∈ {D,E,G,S,W,V} 102 P2 ∈ {P}
P1 ∈ {R}
102 P1' ∈ {A,I,L,M,F,V} 103 P4 ∉ {S}
P2 ∈ {P}
P1 ∈ {R}
103 P1' ∈ {A,I,L,M,F,V} 104 P4 ∉ {R,N,Q,E,K,S}
P2' ∉ {P} P3 ∈ {Q}
P2 ∈ {P}
P1 ∈ {R}
105 P4 ∈ {A,G,I,L,M,F,T,V}
P3 ∈ {A,G,I,L,F,T,V,W}
P2 ∈ {P}
P1 ∈ {R}
P1' ∉ {D,E}
Rules extracted with OSRE from the artificial data sets (cf. Table 1). 
The left column for each data set shows the number of peptides used 
to extract the rules.
OSRE rules' performance on the HIV-1 PR 746 data set Figure 1
OSRE rules' performance on the HIV-1 PR 746 data 
set. The performance of the OSRE rules on the HIV-1 PR 
746 data. The x-axis shows the number of rules used in the 
prediction. The y-axis shows the CV accuracy. The error 
bars are 1.96 times the binomial standard deviations. The 
horizontal lines show the accuracy when all rules (even more 
than 5) are used. The accuracy for zero rules is the default 
accuracy, when all peptides are classified as the majority 
class.
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OSRE rules' performance on the HIV-1 PR 1625 data set Figure 2
OSRE rules' performance on the HIV-1 PR 1625 data 
set. The performance of the OSRE rules on the 1625 peptide 
HIV-1 PR data. The x-axis shows the number of rules used in 
the prediction. The y-axis shows the CV accuracy (%). The 
error bars are 1.96 times the binomial standard deviations. 
The horizontal lines show the accuracy when all rules (even 
more than 5) are used. The accuracy for zero rules is the 
default accuracy, when all peptides are classified as the 
majority class.
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tivity (true positive fraction), specificity (true negative
fraction), and positive likelihood ratio. These are defined
as:
Sensitivity
True Positives
True Positives False Negatives
=
+
(1)
Specificity
True Negatives
True Negatives False Positives
=
+
(2)
Positive Likelihood Ratio
Sensitivity
Specificity
=
− 1
(3)
Table 3: Consensus rules for the HIV-1 PR data sets. 
HIV-1 PR 746 peptide set HIV-1 PR 1625 peptide set
HIVA1 P3 ∉ {N} HIVA2 P4 ∉ {N,C,I}
P2 ∉ {Q,L,K,S} P2 ∉ {Q,K,P,S}
P1 ∈ {G,L,M,F,Y} P1 ∈ {L,M,F,Y}
P1' ∈ {H,I,L,M,F,P,Y,V} P1' ∉ {R,N,D,C,Q,E,K,S,T}
P2' ∉ {R,N,D,G,H,K,P,S} P2' ∉ {R,N,D,G,H,K}
P3' ∉ { K }
HIVB1 P1 ∉ {Q,K,T,V} HIVB2 P4 ∉ {N,C,I,K,M,F,W,Y}
P1' ∈ {L,F,P,Y} P3 ∉ {N,C,V}
P2' ∉ {R,N,D,G,H,K,S,T,Y} P2 ∉ {K}
P3' ∉ {N,H,I,L,K,P,S} P1 ∉ {R,Q,E,K,T}
P4' ∉ {N,Q,I,M,V} P1' ∉ {R,N,D,C,Q,E,K,S,T}
P2' ∈ {A,C,Q,E,I,L,S,V}
P3' ∈ {A,C,Q,M,F,Y}
HIVC1 P2 ∉ {Q,L,K,S} HIVC2 P4 ∉ {N,C,I,K,M,F,W,Y}
P1 ∉ {K,T,V} P3 ∉ {N,V}
P2' ∈ {E} P2 ∈ {A,C,I,M,F,V}
P3' ∉ {N} P1 ∉ {R,Q,E,K,P,T}
P1' ∉ {R,N,D,C,Q,E,K,S,T}
P2' ∈ {A,C,Q,I,L,S,V}
P3' ∉ {N,K,P}
HIVD1 P3 ∉ {N,C,S,V} HIVD2 P4 ∉ {C,I,Y}
P2 ∈ {I,V} P3 ∉ {N,V}
P1 ∉ {Q,K,P,T,V} P2 ∈ {A,C,I,M,F,T,V}
P1' ∉ {D,Q,K,S} P1 ∈ {A,L,M,F,Y}
P2' ∉ {R,N,D,G,K} P1' ∉ {K}
P3' ∉ {N} P2' ∈ {A,E,I,L,S,V}
P4' ∉ {A,N,Q,I,M,W,Y,V} P3' ∉ {N,I,K,P}
HIVE1 P1 ∈ {L,M,F,Y} HIVE2 P2 ∈ {A,C,I,M,F,V}
P1' ∈ {L,M,F,P,Y} P1 ∉ {R,Q,E,K}
P4' ∉ {A,N,I,M,Y,V} P2' ∈ {A,C,Q,E,I,L,S,T,V}
P3' ∈ {A,C,M,F,Y}
Consensus rules for the HIV-1 PR data sets. The rules are listed in the priority order given by the OSRE method. The text in italics is the label for 
each rule.
Table 4: Fidelity for HIV-1 PR rules. 
Rules used Accuracy 746 HIV-1 Accuracy 1621 HIV-1
HIVA1, HIVB1, ..., HIVE1 92.9% 90.0%
HIVA2, HIVB2, ..., HIVE2 92.2% 94.9%
[17] Fig. 1a 63.4% 85.4%
[17] Fig. 1b 75.3% 65.2%
[17] Table III 63.0% 85.1%
[17] Table IV 75.5% 65.3%
The fidelity of the rules for the HIV-1 PR data sets (cf. Table 3).BMC Bioinformatics 2009, 10:149 http://www.biomedcentral.com/1471-2105/10/149
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The positive likelihood ratio measures how much better
the odds of correctly predicting a cleavage location with
the rule set are than predicting randomly according to
prevalence.
The sensitivity and specificity are usually shown together
in a so-called receiver operator characteristic (ROC) curve.
The ROC plots for the OSRE HIV-1 rules are shown in Fig-
ure 3 and Figure 4, together with the same values for the
rough set theory rules [17], the recently published HIV-
cleave web-server [37], and a linear support vector
machine [38], which was the best predictor we had hith-
erto tried for this problem. The positive likelihood ratio is
shown in Table 5, together with corresponding sensitivity
and specificity values.
HCV NS3 protease
Rule extraction
The OSRE method was applied to the HCV NS3 data in a
corresponding way as for the HIV-1 PR data. The CV out-
of-sample error as a function of the number of rules is
shown in Figure 5. The accuracy when using all rules is
95%. This is close to the performance of a non-rule-based
linear support vector machine classifier with tuned
"slack", which has an accuracy of 97%, and it is the hith-
erto best result using a rule based method for HCV NS3.
The consensus rules for HCV NS3 protease are listed in
Table 6. Their fidelity, shown in Table 7, is similar to the
out of sample accuracy (95%).
Out-of-sample tests
Applying the HCV rules to the NS3 protease sequence (the
NS3 internal test data set) produces 46 predicted internal
cleavage sites, which are listed in Table 8. These can be
compared to observed internal cleavages for the NS3 pro-
tease [32-34].
Yang et al. [32] report two internal cleavages of NS3 which
are cleaved by the NS3 protease itself together with the
NS4A co-factor. These are HLIFCH-SKKK (H369) and
VSVIPT-SGDV (T402). The latter of these is predicted by
the HCV rules (Table 8). The first one is not predicted to
be cleaved but the nearby cleavage RHLIFC-HSKK (C368)
is predicted. It is probably also the correct cleavage site
(see discussion).
Kou et al. [33] tested the internal cleavages at HLIFCH-
SKKK (which we believe is actually RHLIFC-HSKK) and
VSVIPT-SGDV for sensitivity to genotype. They found that
the latter cleavage had genotype specificity, i.e. NS3 pro-
tease from HCV-1b could not cleave NS3 protease from
genotype HCV-2a, and vice versa. The HCV rules predict
Table 5: Positive likelihood ratios for HIV-1 PR rules. 
Rules used Positive likelihood ratio Sensitivity Specificity
HIVA1 11.3 31% 97%
HIVA1, HIVB1 6.2 41% 93%
HIVA1, HIVB1, HIVC1 5.2 57% 89%
HIVA1, HIVB1, HIVC1, HIVD1 4.7 61% 87%
HIVA1, HIVB1, HIVC1, HIVD1, HIVE1 4.7 64% 86%
HIVA2 11.3 33% 97%
HIVA2, HIVB2 6.8 40% 94%
HIVA2, HIVB2, HIVC2 5.6 44% 92%
HIVA2, HIVB2, HIVC2, HIVD2 5.2 48% 91%
HIVA2, HIVB2, HIVC2, HIVD2, HIVE2 4.5 49% 89%
Kontijevskis et al. [17] Fig. 1a 2.1 3% 99%
Kontijevskis et al. [17] Fig. 1b 1.7 87% 49%
Kontijevskis et al. [17] Table III 0.8 3% 97%
Kontijevskis et al. [17] Table IV 1.7 87% 49%
HIVcleave [37] 45.4 2% 100%
HIVcleave [37] 3.0 32% 89%
HIVcleave [37] 2.8 50% 82%
L-SVM [38] 29.1 2% 100%
L-SVM [38] 10.6 31% 97%
L-SVM [38] 6.7 50% 93%
The positive likelihood ratios for different rules and predictors on the HIV-1 3261 data set. The results are shown for the OSRE HIV-1 rules and 
the Kontijevskis et al. rough set theory rules [17], together with some reference values for the HIVcleave web server [37] and a linear support 
vector machine [38].BMC Bioinformatics 2009, 10:149 http://www.biomedcentral.com/1471-2105/10/149
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the same; NS3 from genotypes HCV-1a and HCV-1b is
predicted to be cleaved at this site by the HCV rules, but
not NS3 from genotypes HCV-2a, HCV-2b or HCV-2c.
Hou et al. [34] report an alternative cleavage of NS3/4A,
which can be observed when the wild type NS3/4A cleav-
age site is mutated so that it is not cleaved. They estimate
that the alternative cleavage site (an internal NS3 cleavage
site) is located about 6 kDa upstream from the wild type
cleavage site, based on their observations of two 12 kDa
and 67 kDa fragments that appear when the wild type
cleavage site is mutated, but they were unable to find the
location of the alternative cleavage site although they
tested to mutate sites that were 6 kDa upstream from the
NS3/4A cleavage site [34]. It is therefore not possible to
test whether the HCV rules would match this site. How-
ever, we can predict the possible cleavage sites under the
assumption that the HCV rules are correct. It is peculiar
that Hou et al. report observed masses for the NS3 and the
NS3-NS4A complex which are larger (73 kDa and 80 kDa,
respectively) than their molecular masses (which are 67
kDa and 73 kDa, respectively). It is possible that the rea-
son is that there was something extra (with mass 6–7 kDa)
sitting on the N-terminal side of the cloned NS3+NS4A
complex, which was not cleaved off. This means that one
should look for NS3 cleavage fragments of about 61 kDa
and 6 kDa (since the NS4A has a mass just below 6 kDa).
If this is correct then the alternative cleavage site could be
in any of four positions (cf. Table 8): C47, C52, C568 or
C584.
The HCV rules predict at least two correct cleavage sites
(out of 46 potential sites), no false negatives and 575 (out
The receiver operator characteristic (ROC) for the OSRE  rules’ accuracy on the out-of-sample HIV-1 PR 3261 data set Figure 3
The receiver operator characteristic (ROC) for the 
OSRE rules’ accuracy on the out-of-sample HIV-1 PR 
3261 data set. The triangles show the results for the OSRE 
HIV-1 PR 746 rules and the circles show the results for the 
OSRE HIV-1 PR 1625 rules (the five symbols correspond to 
results using 1, 2, 3, 4, and 5 rules, respectively). The dia-
monds and stars show the rough set rules’ prediction accu-
racy, Table III and Fig. 1b in [17]. The diamonds and stars 
show the results when 1, 2, 3, ..., and 9 rules are used from 
[17]. The squares and the crosses in the detail Figure, Fig. 4, 
are the results for Table IV and Fig. 1a in [17]. The dots show 
the prediction accuracy for the HIVcleave web-server [37]. 
The solid curve shows the ROC curve for the hitherto best 
predictor, a linear support vector machine trained on the 
HIV-1 PR 1625 data set [38], which does not provide any 
rules. The dashed diagonal line marks the expected results 
for random prediction.
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ROC for different rule based systems on the out-of-sample  HIV-1 PR 3261 – detail Figure 4
ROC for different rule based systems on the out-of-
sample HIV-1 PR 3261 – detail. Detail of the receiver 
operator characteristic (ROC) for the OSRE rules' accuracy 
on the out-of-sample HIV-1 PR 3261 data set. The squares 
and the crosses are the results for Table 4 and Fig. 1a in [17]. 
The squares show the results when using 1, 2, 3, ..., and 10 
rules from Fig. 1a in [17] and the crosses for Table 4 in [17]. 
The dots show the prediction accuracy for the HIVcleave 
web-server [37]. The solid curve shows the ROC curve for 
the hitherto best predictor, a linear support vector machine 
trained on the HIV-1 PR 1625 data set [38], which does not 
provide any rules. The dashed diagonal line marks the 
expected results for random prediction.
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of 621) true negatives for the NS3 internal test data. This
indicates an out-of-sample specificity (true negative rate)
of 93% and a sensitivity (true positive rate) of 100% (no
false negatives) for the HCV rules.
The HCV rules produce 196 possible cleavage sites on the
TLR3 test data set (2805 decamers). Of these, only one is
a verified cleavage site, PSSTP-CSAHL in TICAM-1 [35],
which matches a decamer in the HCV NS3 data set. None
of the remaining 2804 decamers match any decamers in
the HCV NS3 data set. Thus, there are (at most) 195 false
positives and 2609 true negatives. This indicates an out-
of-sample specificity of 2609/(195 + 2609) = 93%, which
agrees with the estimate from the NS3 internal test data.
Kim et al. [36] performed an in vivo determination of HCV
NS3 substrate specificity, using a genetic assay that pro-
duces random sequences based on the NS4B/5A cleavage
site in HCV. They list 69 decamers that are especially good
substrates for NS3 in vivo. Table 9 shows these 69 decam-
ers (plus a consensus sequence suggested by Kim et al.)
and how they match the HCV rules. Only one of the 69
decamers does not match any HCV rule. Most of the other
decamers match the rule HCVA and many match more
than one rule. This indicates an out-of-sample sensitivity
of 68/(68 + 1) = 99%, which agrees well with the estimate
from the NS3 internal test data.
If the estimates of sensitivity and specificity are correct,
then the positive likelihood ratio for the OSRE HCV rules
would be 14.
Discussion
The artificial data
The results on the two artificial problems illustrate two
things. First, OSRE quickly finds rules that are very close
to the generating rules in terms of classification accuracy.
Secondly, where an identified rule is not completely cor-
rect but the correction refers to rare events, then many
examples are needed before the rare cases are represented
in sufficient number to affect the performance ranking of
the rule set and hence generate the required update.
The difficulty with artificial data set B lies in the very low
probability for observing false positives once the rule (P2
Performance of OSRE rules on the HCV NS3 data set Figure 5
Performance of OSRE rules on the HCV NS3 data 
set. The performance of the OSRE rules on the 939 peptide 
HCV NS3 data. The x-axis shows the number of rules used 
in the prediction. The y-axis shows the out-of-sample accu-
racy (%). The error bars are 1.96 times the binomial standard 
deviations. The horizontal lines show the accuracy when all 
rules are used. The accuracy for zero rules is the default 
accuracy, when all peptides are classified as the majority 
class.
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HCV data (939 decamers), 10−fold CV Table 6: Consensus rules for the HCV NS3 data set. 
HCV NS3 peptide set
HCVA P3 ∉ {K}
P1 ∈ {C}
P1' ∉ {P}
HCVB P6 ∈ {A,N,D,C,E,I,K,M,F,P}
P5 ∉ {I}
P4 ∉ {N,D,Q,G,L,F,P,S,V}
P3 ∈ {R,E,G,I,L,T,V}
P1 ∉ {R,P,Y}
P1' ∈ {A,R,N,D,H,M,S,W,Y}
P3' ∉ {Q,E,I,L,M,P,V}
HCVC P4 ∉ {S}
P3 ∈ {R,E,G,I,F,T,V}
P2 ∉ {C,L,S,T}
P1 ∉ {R,D,P,Y}
P1' ∉ {C,Q,E,G,I,L,K,P,T,V}
P2' ∉ {P}
P3' ∉ {P}
P4' ∉ {A,R,D,E,G,I,P,S,T}
HCVD P6 ∈ {C}
P4 ∈ {R,C,E,I,M,T,V}
P4' ∈ {C,W,Y,V}
Consensus rules for the HCV NS3 data set (939 peptides). The rules 
are listed in the priority order given by the OSRE method. The text in 
italics is the label for each rule.
Table 7: Fidelity for HCV NS3 rules. 
Rules used Accuracy
HCV NS3
HCVA, HCVB, HCVC, HCVD 94.7%
The fidelity of the rules for the HCV NS3 data set.BMC Bioinformatics 2009, 10:149 http://www.biomedcentral.com/1471-2105/10/149
Page 11 of 17
(page number not for citation purposes)
∈ {P} AND P1 ∈ {R}) has been learned. For example, the
training data set with 100,000 observations has 50,002
positive examples and 49,998 negative examples. All the
positive examples (of course) match the rule but only 97
of the negative examples (0.2% of the negative examples)
match the rule and are thus counterexamples that point to
that the rule must be modified.
In summary, OSRE finds a very good rule already with 100
samples and is able to find the corrections to this rule
Table 8: The HCV NS3 rules applied to the NS3 protease sequence. 
P1 Decamer Rule match Mass (kDa) Mass (kDa)
C16 RGLLGCIITS HCVA 1.7 65.6
C47 TFLATCINGV HCVA 5.0 62.3
C52 CINGVCWTVY HCVA, HCVC 5.5 61.8
Q73 KGPVIQMYTN HCVC 7.7 59.6
M74 GPVIQMYTNV HCVC 7.8 59.4
V78 QMYTNVDQDL HCVC 8.3 59.0
C97 RSLTPCTCGS HCVA 10.3 56.9
C99 LTPCTCGSSD HCVA 10.5 56.7
S102 CTCGSSDLYL HCVB 10.7 56.5
T108 DLYLVTRHAD HCVB 11.4 55.8
G120 PVRRRGDSRG HCVB 12.8 54.4
S122 RRRGDSRGSL HCVC 13.0 54.2
I132 LSPRPISYLK HCVC 14.1 53.1
G137 ISYLKGSSGG HCVB 14.7 52.6
C159 FRAAVCTRGV HCVA 16.7 50.5
V163 VCTRGVAKAV HCVC 17.1 50.1
K165 TRGVAKAVDF HCVC 17.3 49.9
Q195 PPAVPQSFQV HCVC 20.6 46.6
A240 TLGFGAYMSK HCVC 25.1 42.2
C279 LADGGCSGGA HCVA 29.2 38.1
C289 YDIIICDECH HCVA, HCVC 30.2 37.1
C292 IICDECHSTD HCVA 30.5 36.7
G314 QAETAGARLV HCVC 32.6 34.6
V339 PNIEEVALST HCVB 35.2 32.0
L341 IEEVALSTTG HCVB 35.4 31.9
C368 RHLIFCHSKK HCVA, HCVC 38.3 28.9
N387 VALGINAVAY HCVC 40.3 26.9
L395 AYYRGLDVSV HCVB, HCVC 41.2 26.0
T402 VSVIPTSGDV HCVC 41.9 25.3
C428 DSVIDCNTCV HCVA, HCVC 44.5 22.7
C431 IDCNTCVTQT HCVA 44.9 22.4
S488 SGMFDSSVLC HCVC 51.2 16.1
C492 DSSVLCECYD HCVA 51.6 15.7
C494 SVLCECYDAG HCVA 51.8 15.4
A497 CECYDAGCAW HCVD 52.1 15.1
C499 CYDAGCAWYE HCVA 52.3 14.9
V511 PAETTVRLRA HCVB 53.6 13.6
L513 ETTVRLRAYM HCVB, HCVC 53.9 13.3
C525 PGLPVCQDHL HCVA 55.2 12.0
V535 EFWEGVFTGL HCVC 56.5 10.8
I542 TGLTHIDAHF HCVC 57.2 10.0
Q552 LSQTKQSGEN HCVC 58.4 8.8
A562 FPYLVAYQAT HCVB 59.5 7.8
C568 YQATVCARAQ HCVA, HCVC 60.1 7.1
C584 DQMWKCLIRL HCVA 62.0 5.2
C622 KYIMTCMSAD HCVA 66.3 1.0
The table shows the result of applying the HCV NS3 cleavage rules to the NS3 protease amino acid sequence. Only decamers that are predicted to 
be cleaved are listed. The first column mentions the amino acid and the position in the NS3 sequence that occupies the P1 position in the decamer. 
The second column lists the decamer. The third column shows which HCV NS3 rules that the decamer matches to. The fourth and fifth column 
show the molecular masses of the cleavage products if NS3 is cleaved in that position.BMC Bioinformatics 2009, 10:149 http://www.biomedcentral.com/1471-2105/10/149
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from a mere additional 97 false positives in the case of
data set B. This must be considered a very good perform-
ance.
HIV-1 PR data
Table 4 shows that the OSRE rules have a higher fidelity to
the HIV-1 PR data sets than rules extracted using rough set
theory [17], i.e. the OSRE rules are a more faithful descrip-
tion of the data used to generate them. The out-of-sample
test, Figure 3, shows that the OSRE rules have excellent
predictive power, matching that of the hitherto state-of-
the-art predictor, the linear support vector machine [38],
which is not a rule based method. This is a positive sur-
prise since there is usually a trade-off between accuracy
and comprehensibility. Other previously suggested pre-
dictors (rule based or not) have significantly worse accu-
racy than the OSRE rules and the linear support vector
machine. These include a recently published HIV cleave
web-server [37] and the rough set theory rules [17]. The
rough set theory can produce better results if many more
(hundreds of) rules are used but the comprehensibility is
then definitely sacrificed [17]. The OSRE rules for HIV-1
protease are, on the other hand, both compact and accu-
rate.
The rough set theory approach uses several physicochem-
ical properties for the amino acids and one might believe
that this should produce a better model than just using
letter codes. The results here, however, indicate that this is
not at all the case; conjunctive rules with simple amino
acid letter codes are shorter, better predictors, and have
higher fidelity to the data. Also, the OSRE method is fast;
Table 9: Applying the HCV NS3 rules to the NS3 in vivo test data. 
Decamer Rule match Decamer Rule match
DCYVYCSGSW HCVA, HCVB, HCVC DCSQPCAGSW HCVA
DCAVTCSGSW HCVA, HCVB DCIIVCAGSW HCVA, HCVB, HCVC
DCAVRCSGSW HCVA, HCVB, HCVC DCQQLCAGSW HCVA
DCIKCCSGSW - DCPSPCAGSW HCVA
DCVSNCSGSW HCVA DCAILCAGSW HCVA, HCVB
DCVMKCSGSW HCVA DCIMPCAGSW HCVA
DCATTCSGSW HCVA, HCVB DCVRMCAGSW HCVA, HCVC
DCTQMCSGSW HCVA DCSVLCAGSW HCVA
DCLDLCSGSW HCVA DCYRPCAGSW HCVA, HCVB, HCVC
DCVTPCSGSW HCVA, HCVC DCLCLCAGSW HCVA
DCVSLCSGSW HCVA DCAVCCAGSW HCVA, HCVB
DCPLACSGSW HCVA DCPIMCAGSW HCVA, HCVC
DCMCDCSGSW HCVA DCHQMCAGSW HCVA
DCVLRCSGSW HCVA DCWTPCAGSW HCVA, HCVB, HCVC
DCAVTCSGSW HCVA, HCVB DCIIKCCGSW HCVA
DCSVRCSGSW HCVA DCIMECCGSW HCVA
DCSHPCSGSW HCVA DCSQLCCGSW HCVA
DCCVRCSGSW HCVA, HCVB, HCVC DCTVACTGSW HCVA
DCSVLCSGSW HCVA DCLVACTGSW HCVA
DCRVRCSGSW HCVA, HCVB, HCVC DCPCPCTGSW HCVA
DCVTPCSGSW HCVA, HCVC DCLELCTGSW HCVA
DCIYICSGSW HCVA DCLVACTGSW HCVA
DCRLPCSGSW HCVA, HCVB DCQIICTGSW HCVA
DCYERCSGSW HCVA, HCVB, HCVC DCVVCCGGSW HCVA
DCAVLCSGSW HCVA, HCVB DCTVTTSGSW HCVB
DCVRLCSGSW HCVA DCTVETSGSW HCVB, HCVC
DCPTNCSGSW HCVA, HCVC DCSVVCSSSW HCVA
DCPRLCSGSW HCVA DCSVACSQSW HCVA
DCVSNCSGSW HCVA DCSTLCSTSW HCVA
DCRIPCSGSW HCVA, HCVB, HCVC DCSITCAQSW HCVA
DCVSNCSGSW HCVA DCSVLCARSW HCVA
DCFAMCSGSW HCVA DCSVPCTGSW HCVA
DCTIKCAGSW HCVA, HCVB, HCVC DCSLPCGSSW HCVA
DCLITCAGSW HCVA DCSAPCGSSW HCVA
DCKVTCAGSW HCVA, HCVB DCVVPCSGSW HCVA, HCVC (*)
The table shows the result of applying the HCV NS3 cleavage rules to the 69 decamers listed as especially good substrates in vivo by Kim et al. [36]. 
The first and third column show the decamers and the second and fourth column show the HCV rules that it matches (if any). The last (70th) 
sequence (DCVVPCSGSW), marked with (*), is the consensus sequence tested by Kim et al., this sequence is already in the HCV NS3 data set and 
is thus not an out-of-sample prediction.BMC Bioinformatics 2009, 10:149 http://www.biomedcentral.com/1471-2105/10/149
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it will produce a small (comprehensible) rule set for the
data in this study in the matter of minutes (the timing is
discussed in the Methods section).
The OSRE rules for positions P1 and P1' are the most con-
sistent rules and agree with earlier findings [15,39,40] for
HIV-1 PR: large hydrophobic residues are preferred in
position P1 and hydrophobic residues are preferred in
position P1'. The OSRE consensus rules and the rough set
rules do not agree completely. The rough set rules for
cleaved peptides have, e.g., P3 ∈ {C} which does not
occur very often in the OSRE consensus rules. Another dif-
ference is P1' ∈ {D,C,K} for the rough set rules but not for
the OSRE rules. We cannot with certainty say whether the
OSRE or the rough set rules are more correct, but the fact
that the OSRE rules have a higher fidelity to the data sets
indicates that the OSRE rules would be more correct.
The HIV-1 protease cleavage rules based on the 1625 data
set, listed in in Table 3, require at least four residues to be
specified for cleavage. This is different from Kontijevskis et
al. [17], who find that three specified residues are suffi-
cient. However, this is probably not a significant differ-
ence (the HIV-1 protease cleavage rules for the 746 data
set contain one rule, HIVE1, where three positions are suf-
ficient).
It is difficult, and hardly worthwhile, to compare the
OSRE results for the HIV-1 PR data with other earlier rule
extraction approaches, e.g. [18,20,41,42], except the
rough set rule method. Earlier results have been based on
a much smaller data set (362 peptides) and tend to refer
to single amino acids in single positions and not groups
of amino acids.
The two rules that agree most for the HIV-1 PR 746 and
HIV-1 PR 1625 data sets are HIVA1 and HIVA2; 76% of
the octamers that match HIVA1 also match HIVA2 and
69% of the octamers that match HIVA2 also match
HIVA1, see Table 10. It is therefore reasonable to create a
new consensus sequence by building a joint rule from
HIVA1 and HIVA2, i.e. a rule that describes all octamers
that match both HIVA1 and HIVA2. This consensus
sequence is X-X- [ARNDCEGHIMFTWYV]- [LMFY]-
[HILMFPYV]- [ACQEILMFTWYV]-X-X, where X denotes
any amino acid. The sensitivity, specificity and positive
likelihood ratio for this consensus sequence, when evalu-
ated on the HIV-1 3261 PR data set, are 28%, 99% and 24,
respectively. No other predictor is as accurate as this at this
sensitivity level (cf. Table 5). It is notable that the consen-
sus sequence only considers positions P2-P1-P1'-P2', i.e.
not the full eight residue sequence.
HCV NS3 data
A cysteine (C) in position P1 is considered to be the most
important determinant for cleavage by HCV NS3/4A [31].
This is only reflected in the rule HCVA; the other rules are
much less specific about the P1 position. Urbani et al. [27]
conclude that the specificity is quite broad unless for the
requirement for a small hydrophobic residue (e.g. C or T)
in position P1. The OSRE HCV rule set indicates that the
cysteine in position P1 is the dominating cleavage proc-
ess: 10% of all decamers match the rule P1 ∈ {T,C}, 9%
of all decamers match the rule HCVA and about 11% of
all decamers match any of the OSRE HCV rules. This
means that roughly 80% of the decamers that are cleaved
by HCV NS3 (as predicted by the OSRE rules) match the
rule HCVA.
The standard HCV NS3/4A cleavage rule [23,31,43] (P6 ∈
{E,D} AND P1 ∈ {T,C} AND P1' ∈ {A,S}) is much more
specific than the OSRE HCV rules; only 0.1% of all possi-
ble decamers match this standard rule. Kim et al. [36] sug-
gest an even more restrictive cleavage rule (consensus
sequence) based on their in vivo studies: (P6 ∈ {E,D}
AND P4 ∈ {V} AND P3 ∈ {L,P} AND P1 ∈ {C} AND P1'
Table 10: Mixing of HIV-1 rules.
HIV.. ..A1 ..B1 ..C1 ..D1 ..E1 ..A2 ..B2 ..C2 ..D2 ..E2
HIVA1 4.56% 1.90% 0.36% 0.27% 1.60% 3.45% 0.43% 0.41% 0.43% 0.29%
HIVB1 4.29% 0.31% 0.19% 0.93% 0.73% 0.53% 0.31% 0.16% 0.28%
HIVC1 3.23% 0.14% 0.12% 0.29% 0.24% 0.25% 0.25% 0.26%
HIVD1 2.05% 0.17% 0.28% 0.12% 0.31% 0.20% 0.22%
HIVE1 3.50% 1.58% 0.20% 0.17% 0.22% 0.12%
HIVA2 4.97% 0.54% 0.53% 0.67% 0.32%
HIVB2 2.56% 0.62% 0.22% 0.63%
HIVC2 1.86% 0.53% 0.55%
HIVD2 1.53% 0.41%
HIVE2 2.70%
There are 208 possible octamers.
The fractions of these octamers that match to each OSRE HIV-1 rule, and to more than one rule, are shown here. The diagonal elements in the 
table show the fraction of the possible octamers that match one rule. The off-diagonal elements in the table show what fraction of the octamers 
that match both rules.BMC Bioinformatics 2009, 10:149 http://www.biomedcentral.com/1471-2105/10/149
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∈ {A,S}). Only one in eight million decamers match this
consensus sequence. None of the decamers studied by
Kim et al. [36], except the one they handcraft to fit, match
their consensus sequence.
None of the OSRE HCV rules support P6 ∈ {E,D} and P1'
∈ {A,S}. Thus, it cannot be said that the OSRE HCV rules
are in strong agreement with previously reported consen-
sus sequences. However, the OSRE HCV rules are more
accurate at predicting the cleavage sites. They are domi-
nated by HCVA and HCVC, which together match about
10% of all decamers, see Table 11. The two rules have
quite a small overlap, 7% of the decamers that match
HCVA also match HCVC, and 6% of the decamers that
match HCVC also match HCVA (cf. Table 11). This indi-
cates that there are two different processes taking place,
one described by HCVA and the other described by HCVB
and HCVC, which have a higher overlap. The contribution
from HCVD is quite small and it can probably be ignored.
The positive likelihood ratio for the OSRE HCV rules is
estimated to be 0.99/(1-0.93) ≈ 14, which is the same as
for the HIV-1 PR consensus sequence, but the sensitivity is
much higher for HCV NS3/4A than for HIV-1 PR.
It was mentioned in the result section that we believe the
internal cleavage of NS3 to be at C368 (RHLIFC-HSKK)
and not at H369 (HLIFCH-SKKK) that Yang et al. [32]
report. There are two reasons for this. One is that the HCV
rules match one site and not the other. The other reason is
that the experimental data presented by Yang et al. fits
also with a cleavage at C368. They [32] test their predicted
location of the cleavage site by several pairwise mutations
in the HCV polyprotein: ...RHLIFCHSKKKC... →
...RHLPGCHSKKKC... (pNS34A-M4); ...RHLIFCPG-
KKKC... (pNS34A-M5); ...RHLIFCHSKPGC... (pNS34A-
M6); and ...RHLIFCHSKKPG... (pNS34A-M7). Yang et al.
note that the internal cleavage is blocked when the muta-
tion is pNS34A-M5, whereas the internal cleavage occurs
in all other cases. These observations are perfectly consist-
ent with cleavage at C368 (between C and H) if the rule
HCVA is correct.
It is not worthwhile to compare the OSRE HCV rules to
previous automated rule extraction (and prediction) work
on HCV NS3 protease since these have been based on a
data set with many errors in it.
The HCV NS3 problem seems to be easier than the HIV-1
PR problem. Fewer rules are required and the OSRE NS3
rules are more accurate than the OSRE HIV-1 PR rules.
Conclusion
A methodology that combines the OSRE rule extraction
method and spectral clustering was introduced for effi-
ciently, i.e. quickly and accurately, extracting accurate and
comprehensible specificity rules for proteases, rules that
also had a high fidelity to the data used to create them.
The approach was demonstrated on two medically impor-
tant protease cases, HIV-1 protease and HCV NS3/4A pro-
tease. The HIV-1 protease rules were shown to be more
accurate than previous state-of-the-art rule extraction
results on a large HIV-1 protease out-of-sample test data
set. The proposed methodology achieved this perform-
ance using fewer rules than previous approaches and with
a higher fidelity to the data set that had been used to create
the rules.
The HCV NS3/4A protease rules were shown to fit very
well with experimental findings for the HCV NS3 pro-
tease. The rules were used to correct the position of an
internal cleavage site in HCV NS3, which demonstrates
the usefulness of accurate and comprehensible rules when
interpreting experimental data.
The results indicate that the HCV NS3/4A protease cleav-
age is a simpler problem than the HIV-1 protease cleavage.
In summary, the OSRE approach yields rules that are sim-
pler and more accurate than other rule extraction methods
for protease specificity problems, and it is significantly
faster. It does so by using conjunctive low-order rules, i.e.
rules with few arguments and in a form that is commonly
used to describe protease specificities.
Methods
Orthogonal search-based rule extraction (OSRE)
The OSRE algorithm [44] finds conjunctive rules for clas-
sifications from any classifier that produces a smooth
response surface. It is an efficient method to find low-
order rules from labeled data. Given a data set with an
associated classification label, the method starts by fitting
the response surface that best classifies the data. This is a
smooth surface in data space which separates it into differ-
ent regions by means of generic, non-linear decision
boundaries. This fit to the data must be obtained by a
robust statistical methodology, to ensure good out-of-
sample generalization [44]. This step is essential in order
Table 11: Mixing of HCV NS3 rules. 
HCVA HCVB HCVC HCVD
HCVA 4.51% 0.16% 0.33% 0.02%
HCVB 2.27% 0.77% 0.02%
HCVC 5.28% 0.04%
HCVD 0.35%
There are 2010 possible decamers. The fractions of these decamers 
that match to each OSRE HCV NS3 rule, and to more than one rule, 
are shown here. The diagonal elements in the table show the fraction 
of the possible octamers that match one rule. The off-diagonal 
elements in the table show what fraction of the decamers that match 
both rules.BMC Bioinformatics 2009, 10:149 http://www.biomedcentral.com/1471-2105/10/149
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to obtain a smooth fit of the data, cutting through noise
and thus avoiding over-fitting. In the first stage of the rule-
extraction algorithm, rules are fitted to the response sur-
face of this statistical model, rather than to the data them-
selves. For this reason, the non-linear model is a multi-
layer perceptron neural network with strong regulariza-
tion using the Bayesian framework of Automatic Rele-
vance Determination [45]. In cases where the data are
linearly separable, this heavy robust regularization will
default to a linear decision boundary. Cycling through the
data, this stage results in the maximal multivariate box,
centered on each data point, which is to one side of the
decision boundary, returning an initial number of rules
equal to the number of data points.
The second stage in the application of OSRE, is to sort the
rules by their performance on the data set, measuring per-
formance by the proportion of actual data points within
each multivariate box, i.e. conjunctive rule, which belongs
in the correct class. This process includes removing boxes
within boxes and selecting the rules with the best balance
between coverage, i.e. true detection rate, and specificity,
i.e. a low false detection rate. This is achieved by starting
with the individual rule whose performance in the ROC
plot is closest to the ideal point with unit sensitivity and
specificity, then adding more rules in a stepwise manner,
each time selecting the best additional rule by measuring
the position of the aggregate rule set in the ROC plot. The
automatic forward selection of the minimal rule set that
best approximates the ideal performance of unit sensitiv-
ity and specificity is a development of the OSRE method-
ology since the publication of the original paper.
By not imposing a requirement of mutual exclusivity
between individual rules and, instead, searching directly
in a multivariate space, rather than in a sequential univar-
iate manner as with most rule extraction methods, it is
found that the well performing rules are of low-order. This
means that the rules are more readily interpretable by
expert users, as they involve fewer arguments. The repre-
sentation framework using multivariate conjunctive rules
at each node in the search hierarchy, rather than univari-
ate nodes in a decision tree, is a particular feature of the
OSRE methodology which makes it more suitable to the
derivation of rule sets that are interpretable by human
experts. In effect, it represents a trade-off between the sim-
plicity in the definition of each node in the tree, which is
now a multivariate vector rather than a scalar node, for
simplicity of the rule set as whole, with fewer and simpler
rules.
The method was originally validated on artificial data [44]
and has since been successfully applied in a number of
practical applications, e.g. [46].
Creating the decision surface is what tends to take the
longest time. This is, however, sometimes available from
a previous study. The rule extraction phases (first and sec-
ond stages) scale, in the current implementation, approx-
imately quadratically with the number of observations.
Running OSRE on HIV-1 data sets of different sizes,
excluding the decision surface creation, takes approxi-
mately 0.5 seconds for 100 observations, 12 seconds for
1600 observations, and 60 seconds for 3200 observations
(on an AMD Athlon 64 Processor 2 GHz 3 GB RAM with
Windows XP SP3). These are indicative times and individ-
ual runs may vary a lot.
Model validation
The OSRE method was applied using ten-fold cross-vali-
dation (CV) on the data sets. This means that the OSRE
method extracted rules using 90% of the data and the
rules were then tested on the remaining 10%, which thus
was a hold-out sample. This was repeated ten times so that
each peptide in the data set had been used out-of-sample
once. The average out-of-sample accuracy over these ten
runs was then used as the expected generalization per-
formance of the OSRE method.
The performance obtained by OSRE on the cleavage data
was obtained by the application of the standard method-
ology as outlined above, rather than by selecting the best
performance from a range of possible methodologies,
which may be biased towards the suitability of the chosen
method to the particular nuances of the data sets under
study. Therefore, it is expected that this performance ben-
efit represents a generic feature of the proposed method-
ology, which will generalize to other cleavage data.
Rule clustering
OSRE produced slightly different rules for each CV subset.
The rules were therefore grouped using the normalized cut
spectral clustering algorithm [47]. The affinity matrix W
used had elements
where dij was the fraction of peptides that the two rules
disagreed on when evaluated on the data set that the rules
were extracted for (i.e. the 1625 HIV-1 PR data set, the 746
HIV-1 PR data set or the 939 HCV NS3 data set). The
number of clusters was set to five, which was a subjective
choice based on the OSRE results and the quality of the
clusterings measured with the Fowlkes-Mallows index
[48]. The iterative clustering method gave slightly differ-
ent results each time it was run. It was therefore repeated
five times and the rules that clustered together all five
w
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times were grouped together. The most common amino
acids in each position within each group then defined the
consensus rule for that group. Two of the five clusters
mixed very much for the HCV NS3 data. These two clus-
ters where joined and there are therefore only four con-
sensus rules for the HCV NS3 data although the clustering
was done with five clusters.
The fidelity of the consensus rules was tested on the data
after the clustering had been done. The consensus rules
(and the number of clusters) were not changed once the
rules had been tested on the data.
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